EIK1003 / IMPACT Therap, Eikon Therap - LARVOL DELTA

Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, in combination with abiraterone in patients with metastatic prostate cancer (mPC) (ESMO 2026) - No abstract available

Clinical • Combination therapy • Metastases • P1/2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, as monotherapy and in combination with paclitaxel (PTX) in advanced solid tumors (ESMO 2026) - No abstract available

Combination therapy • Metastases • Monotherapy • P1/2 data • Oncology • Solid Tumor

A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor EIK1003 as monotherapy and in combination in patients with advanced solid tumors (AACR 2025) - "EIK1003 (IMP1734) is a potent PARP1-selective inhibitor that inhibits tumor growth in nonclinical models and may widen the therapeutic index in tumors where nonselective PARPi have demonstrated efficacy. Study EIK1003-001 (IMP1734-101) is a global, multi-center, Phase 1/2 study evaluating the safety and potential antitumor activity of EIK1003 as monotherapy and in combination with abiraterone or paclitaxel in patients with advanced solid tumors (NCT#06253130). Exploratory endpoints include analysis of pharmacodynamic biomarkers and serial circulating tumor DNA (ctDNA) measurements. This study opened on 11 Dec 2023."

Clinical • First-in-human • Metastases • Monotherapy • P1/2 data • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD • PARP2

Presentations to cover updates across Eikon’s clinical pipeline including: (GlobeNewswire) - "Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4 non-small cell lung cancer (NSCLC); Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors; Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer; Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies."

Clinical data • Non Small Cell Lung Cancer • Prostate Cancer

EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a phase 1/2 study EIK1003-001 in advanced solid tumors. (ASCO 2026) - P1/2 | "EIK1003 + PTX demonstrated a tolerable safety profile in a heavily pre-treated population, with hematologic toxicities comparable to historical PTX use (eg, KN-B96, ESMO 2025). These findings represent the first clinical evidence that PARP1-selective inhibitors can be safely combined with chemotherapy. Extended follow-up of EIK1003 monotherapy confirms durable tolerability with antitumor activity."

Combination therapy • Metastases • Monotherapy • P1/2 data • Breast Cancer • Febrile Neutropenia • HER2 Breast Cancer • HER2 Positive Breast Cancer • Neutropenia • Oncology • Ovarian Cancer • Solid Tumor • HER-2 • PARP2

Cohort 1C: Initial Data on EIK1003 in Combination with Weekly Paclitaxel (GlobeNewswire) - "As of the February 27, 2026 safety data cutoff, 60 patients with platinum-resistant ovarian cancer or HER2-negative breast cancer that failed chemotherapy or hormonal therapy have been treated in Cohort 1C with EIK1003....Among efficacy-evaluable patients in Cohort 1C (n=53), ORR was 24.5%; 12 of 13 responders (92%) had received prior taxane therapy. Objective responses by tumor type were 29.6% (8/27) in platinum-resistant ovarian cancer and 19.2% (5/26) in breast cancer. Duration of response among confirmed responders (n=9) ranged from 1.5 to 11.4 months, with responses ongoing in 3 responders at the efficacy data cutoff of May 4, 2026."

P1/2 data • Platinum resistant • HER2 Negative Breast Cancer • Ovarian Cancer

Cohort 1A: Updated EIK1003 Monotherapy Data (GlobeNewswire) - "As of the enrollment cutoff, 65 patients with breast, ovarian, prostate, or pancreatic cancer have been treated in Cohort 1A with EIK1003 monotherapy....Treatment-emergent adverse events (TEAEs) were reported in 63 of 65 patients (96.9%).....Among efficacy-evaluable patients in Cohort 1A (n=49), ORR was 14.3% overall and 26.7% in PARP-naïve patients. Objective responses by tumor type were 14.8% (4/27) in ovarian cancer, 12.5% (2/16) in breast cancer, and one patient with prostate cancer. Median duration of response among confirmed responders (n=5) was 7.8 months at the efficacy data cutoff of May 4, 2026."

P1/2 data • Breast Cancer • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer

Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (GlobeNewswire) - "Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer ('NSCLC'), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities."

Clinical data • dMMR • MSI-H • P1/2 data • Breast Cancer • Microsatellite Instability • Non Small Cell Lung Cancer • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer

Clinical Updates:…EIK1003 (GlobeNewswire) - "An abstract has been accepted for presentation at the ASCO annual meeting, including updated data from Cohort 1A evaluating EIK1003 as a monotherapy and Cohort 1C evaluating EIK1003 in combination with paclitaxel in patients with platinum-resistant ovarian cancer, or breast cancer patients who are either Her-2 negative, ER+, and hormonal therapy-experienced, or ER- and chemotherapy-experienced. The dose escalation portion of the trial has been completed for Cohorts 1A, 1B...and 1C, with backfill nearing completion. Separately, the first patient has been dosed in a Phase 2 dose optimization trial. In addition, global site selection has been initiated for Cohort 1D, which will evaluate EIK1003 in combination with paclitaxel and platinum-based chemotherapeutic agents in patients with breast or ovarian cancer."

P1/2 data • Platinum resistant • Trial status • Estrogen Receptor Positive Breast Cancer • HER2 Negative Breast Cancer • Ovarian Cancer • Prostate Cancer

EIK1003-001: A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=156 | Recruiting | Sponsor: Eikon Therapeutics | N=72 ➔ 156

Enrollment change • First-in-human • Monotherapy • Breast Cancer • Oncology • Solid Tumor • HRD • MUC16

EIK1003-001: A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=156 | Recruiting | Sponsor: Eikon Therapeutics | N=70 ➔ 156 | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Feb 2026 ➔ Jun 2027

Enrollment change • First-in-human • Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • HRD • MUC16

Safety and efficacy of EIK1003, a selective PARP1 inhibitor, as monotherapy in participants with advanced solid tumors. (ASCO 2025) - "Funded by No funding sources reported Clinical Trial Registration Number: 06253130 Background: PARP inhibitors (PARPi) selectively kill tumor cells with genetic mutations in critical DNA repair genes (eg, BRCA1/2). To date, EIK1001 has demonstrated tolerable safety and encouraging preliminary efficacy. Dose escalation is ongoing. Updated safety and efficacy data will be reported at the time of presentation."

Clinical • Metastases • Monotherapy • Anemia • Breast Cancer • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Neutropenia • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • BRCA1 • BRCA2 • HER-2 • HRD • MUC16 • PARP2

Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting (Businesswire) - "Eikon Therapeutics...announced that new data from its oncology programs will be presented in collaboration with independent investigators at the American Society of Clinical Oncology (ASCO) Annual Meeting....The...posters will spotlight new first-in-human and combination data from Eikon’s two most advanced clinical programs."

Clinical protocol • P1/2 data • Melanoma

Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline (Businesswire) - "Eikon Therapeutics, Inc...announced the initial closing of a $350.7 million Series D financing. Since its founding in 2019, Eikon Therapeutics has privately raised in excess of $1.1 billion to support its mission of developing new medicines to address grievous illnesses....Eikon’s clinical portfolio is anchored by its lead program, EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8 now in a Phase III trial for advanced melanoma.... In parallel, the company is advancing EIK1003, a highly selective PARP1 inhibitor currently undergoing Phase 1 evaluation in patients with breast, ovarian, prostate, or pancreatic cancers, and EIK1004, a central nervous system-penetrant PARP1-selective inhibitor poised to initiate Phase 1 studies targeting brain cancers. Eikon’s early-stage pipeline features, among other undisclosed candidates, two androgen receptor antagonists and an internally derived WRN inhibitor (EIK1005)..."

Financing • Brain Cancer • Breast Cancer • Melanoma • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer

discovery and development of IMP1734 (EIK1003), a potent and selective PARP1 inhibitor (EORTC-NCI-AACR 2024) - P1/2 | "Overall, IMP1734 is a potent and selective PARP1 inhibitor, with robust anti-tumor activity in vivo and decreased potential for hematologic toxicity, making it a promising candidate for further development as a targeted therapy for cancers either as a monotherapy or as combination therapy. IMP1734 is currently being evaluated in a Phase I clinical trial for solid tumors with select HRR gene mutations."

Breast Cancer • Genito-urinary Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • BRCA1 • BRCA2 • HRD • PARP2

A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors. (ASCO 2024) - P1/2 | "Exploratory endpoints include analysis of pharmacodynamic biomarkers, serial ctDNA measurements, and patient quality-of-life measures. This study opened on 11 Dec 2023."

Metastases • P1/2 data • Genito-urinary Cancer • Hematological Disorders • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD • PARP2

Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (Businesswire) - "Separate poster presentations will highlight EIK1001 both in combination with pembrolizumab and chemotherapy (trial in progress) and safety and preliminary efficacy in combination with atezolizumab; A Phase 1 study of the PARP1-selective inhibitor, EIK1003, will be highlighted in a poster presentation (trial in progress)."

P1 data • Trial status • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=70 | Recruiting | Sponsor: Eikon Therapeutics

New P1/2 trial • Oncology • Solid Tumor

Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference (Businesswire) - "EIK1001 Advances to Phase 2: Eikon's most advanced candidate, EIK1001, a systemically administered TLR 7 and 8 co-agonist, has received Investigational New Drug Application (IND) clearance from the U.S. Food and Drug Administration (FDA) and has proceeded into the first of several planned Phase 2 trials focused, in this case, on patients with advanced lung cancer when administered in combination with standard-of-care pembrolizumab plus chemotherapy....EIK1003 Now Enrolling Patients: Eikon's selective PARP1 inhibitor, EIK1003, has entered a Phase 1/2 clinical trial at multiple U.S. sites assessing safety and tolerability in adult patients that have received at least one prior PARP inhibitor treatment for specific solid tumors expressing selected deleterious genetic mutations. International sites will join the trial early in 2024."

IND • Trial status • Lung Cancer • Oncology • Solid Tumor

Eikon Therapeutics Announces Business Update, Highlighting Pipeline and Clinical Development Progress (Businesswire) - "Separately, the FDA has cleared IMP1734, a highly selective PARP1 inhibitor developed in partnership with Impact Therapeutics, for Phase 1 study initiation, which will also begin in the fourth quarter."

IND • New P1 trial • Oncology

Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors (PRNewswire) - "IMPACT Therapeutics...and Eikon Therapeutics...announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors including IMP1734, which is anticipated to enter into Phase I clinical study in 2023. Under the collaboration agreement, Eikon received an exclusive license from Impact to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China (mainland China, Hong Kong, Macau, and Taiwan)."

Licensing / partnership • New P1 trial • Oncology